Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand…
ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent…